PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends PHXM vs. AFMD, OSTX, XCUR, TPST, RVPH, CVM, ANEB, RAPT, LUMO, and ELEVShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Affimed (AFMD), OS Therapies (OSTX), Exicure (XCUR), Tempest Therapeutics (TPST), Reviva Pharmaceuticals (RVPH), CEL-SCI (CVM), Anebulo Pharmaceuticals (ANEB), RAPT Therapeutics (RAPT), Lumos Pharma (LUMO), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Affimed OS Therapies Exicure Tempest Therapeutics Reviva Pharmaceuticals CEL-SCI Anebulo Pharmaceuticals RAPT Therapeutics Lumos Pharma Elevation Oncology Affimed (NASDAQ:AFMD) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Which has higher earnings & valuation, AFMD or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$8.95M4.71-$114.66MN/AN/APHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Do insiders & institutionals believe in AFMD or PHXM? 30.8% of Affimed shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 3.8% of Affimed shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer AFMD or PHXM? In the previous week, Affimed had 10 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 11 mentions for Affimed and 1 mentions for PHAXIAM Therapeutics. Affimed's average media sentiment score of 0.19 beat PHAXIAM Therapeutics' score of 0.00 indicating that Affimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Affimed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral PHAXIAM Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, AFMD or PHXM? Affimed has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Is AFMD or PHXM more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. PHAXIAM Therapeutics' return on equity of 0.00% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Affimed-7,836.26% -193.84% -107.24% PHAXIAM Therapeutics N/A N/A N/A Does the MarketBeat Community prefer AFMD or PHXM? Affimed received 437 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAffimedOutperform Votes43770.14% Underperform Votes18629.86% PHAXIAM TherapeuticsN/AN/A Do analysts prefer AFMD or PHXM? Affimed presently has a consensus target price of $16.00, suggesting a potential upside of 510.69%. Given Affimed's stronger consensus rating and higher probable upside, research analysts clearly believe Affimed is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAffimed beats PHAXIAM Therapeutics on 9 of the 15 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$151.56M$5.21B$8.85BDividend YieldN/A3.64%5.53%4.08%P/E RatioN/A182.3083.3415.60Price / Sales0.3217,316.051,247.8087.92Price / CashN/A12.1540.9736.92Price / Book0.397.557.206.55Net Income-$240,000.00-$19.43M$119.63M$226.22M7 Day PerformanceN/A0.48%2.12%3.77%1 Month PerformanceN/A7.50%-2.43%4.64%1 Year Performance-34.74%29.77%34.55%29.21% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AFMDAffimed3.3906 of 5 stars$2.62-0.8%$16.00+510.7%-47.5%$42.18M$8.95M0.0076Analyst ForecastAnalyst RevisionOSTXOS TherapiesN/A$1.95+4.8%N/AN/A$41.46MN/A0.00N/ANegative NewsXCURExicure1.7772 of 5 stars$18.38+69.2%N/A+3,576.0%$39.89M$28.83M-8.8850Gap UpHigh Trading VolumeTPSTTempest Therapeutics2.2873 of 5 stars$0.91+1.1%$20.00+2,108.7%-78.4%$39.52MN/A-0.5920RVPHReviva Pharmaceuticals2.0625 of 5 stars$1.14-8.1%$15.50+1,259.6%-74.8%$38.12MN/A-1.035CVMCEL-SCIN/A$0.60-1.7%N/A-74.6%$38.02MN/A-1.0343Analyst DowngradeNews CoverageANEBAnebulo Pharmaceuticals2.5299 of 5 stars$1.46-2.7%$8.00+447.9%-30.8%$37.86MN/A-4.874Analyst ForecastNews CoverageRAPTRAPT Therapeutics4.5428 of 5 stars$1.08+2.9%$9.50+779.6%-92.1%$37.76M$1.53M0.0080LUMOLumos Pharma2.62 of 5 stars$4.31-0.5%$8.63+100.1%+39.9%$37.28M$2.05M0.0030ELEVElevation Oncology2.3848 of 5 stars$0.60flat$7.80+1,192.7%+30.7%$35.67MN/A-0.7440News Coverage Related Companies and Tools Related Companies Affimed Competitors OS Therapies Competitors Exicure Competitors Tempest Therapeutics Competitors Reviva Pharmaceuticals Competitors CEL-SCI Competitors Anebulo Pharmaceuticals Competitors RAPT Therapeutics Competitors Lumos Pharma Competitors Elevation Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHXM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
